NCT03072615 (TIPS-SWE) is a clinical trial of Stiffness measurement in Portal Hypertension, sponsored by Jonel Trebicka.

Who is sponsoring NCT03072615?

NCT03072615 is sponsored by Jonel Trebicka.

What drugs are being tested in NCT03072615?

Interventions in NCT03072615: Stiffness measurement.

What condition does NCT03072615 study?

NCT03072615 studies Portal Hypertension, Liver Cirrhoses.

Is NCT03072615 still recruiting?

NCT03072615 is currently completed. Last updated 7 March 2017.

Last reviewed 2017-03-07 · How we verify

NCT03072615: TIPS-SWE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Role of SWE-change After TIPS in the Prediction of Prognosis After TIPS

Completed Last updated 7 March 2017

What this trial tests

trial testing Stiffness measurement in Portal Hypertension in 83 participants. Completed in 29 February 2016.

Timeline

1 April 2013

Primary endpoint
30 November 2015

29 February 2016

Quick facts

Lead sponsor	Jonel Trebicka
Status	Completed
Study type	OBSERVATIONAL
Enrollment	83
Start date	1 April 2013
Primary completion	30 November 2015
Estimated completion	29 February 2016

Drugs / interventions tested

Stiffness measurement

Conditions studied

Portal Hypertension — all drugs for Portal Hypertension →
Liver Cirrhoses — all drugs for Liver Cirrhoses →

Sponsor

Jonel Trebicka

Who can join

18 and older, any sex, with Portal Hypertension or Liver Cirrhoses. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of our prospective multicenter study was to investigate the prognostic value of the acute and long-term changes of liver stiffness in patients receiving a transjugular intrahepatic portosystemic shunt (TIPS).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality.
Jansen C, Möller P, Meyer C, Kolbe CC, et al · · 2018 · cited 63× · PMID 29059466 · DOI 10.1002/hep.29612

Verify or expand the search:

Other recruiting trials for Portal Hypertension

Currently open trials in the same condition.

NCT07439939 — Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Place · recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07419724 — Construction of a Portal Hypertension Biobank · recruiting
NCT07116096 — Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis · NA · recruiting
NCT07080697 — A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hyper · NA · recruiting

Other Jonel Trebicka trials

Trials by the same sponsor.

NCT03056612 — Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03072615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonel Trebicka
Last refreshed: 7 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03072615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing